PacBio to Participate in the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
PacBio (NASDAQ: PACB) management will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 2, 2026 at 2:30 PM ET in Boston.
A live webcast will be available on the company's investor site and a replay will be accessible for at least 30 days, according to PacBio.
Positive
- None.
Negative
- None.
News Market Reaction – PACB
In the Feb 19 session, PACB gained 3.07%, reflecting a moderate positive market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Earnings results | Neutral | +0.0% | Reported Q4 and full‑year 2025 revenue growth with improved non‑GAAP margins. |
| Feb 12 | Partnership news | Positive | +0.0% | Joined iHope initiative as first long‑read sequencing partner for rare diseases. |
| Feb 02 | Asset sale | Positive | -8.8% | Completed sale of short‑read assets to Illumina, receiving $48.1M net cash. |
| Jan 27 | Earnings date notice | Neutral | +2.0% | Announced date and access details for Q4 and full‑year 2025 results call. |
| Jan 12 | Collaboration plans | Positive | +3.6% | Planned collaboration using HiFi long‑read sequencing for ultra‑rare genetic diseases. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent strategic and partnership announcements have sometimes seen muted or even negative next-day moves despite constructive narratives.
Over the last few months, PACB reported Q4 and full‑year 2025 results on Feb 12, 2026, showing revenue growth and improved non‑GAAP margins but large GAAP losses. It completed the sale of short‑read sequencing assets to Illumina, adding about $48.1M in net cash and sharpening focus on long‑read sequencing. Partnerships, including the iHope initiative and a rare‑disease collaboration with n‑Lorem and EspeRare, highlight emphasis on long‑read applications. Today’s conference participation fits into this pattern of ongoing outreach and strategic positioning updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026, at 2:30 PM ET in Boston, MA.
A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
ir@pacb.com
Media:
pr@pacb.com
